



Changes to GLP-1 Drug Coverage – Effective January 1, 2026

If you take a GLP-1 drug for weight loss only, talk to your doctor about other options that can help, such as other drugs, diet changes, exercise, and counseling to support your weight loss goals and overall health.

Wegovy®, Zepbound®, Saxenda®

- If you take one of these three drugs for **weight loss only**, it will no longer be covered. Previously approved requests from your pharmacy provider or prescriber, called prior authorizations (PAs), will end on December 31, 2025.
- Talk to your pharmacy provider or prescriber about submitting a PA request if you take one of the following GLP-1 drugs:
 - Wegovy for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) or cardiovascular disease
 - Zepbound for obstructive sleep apnea (OSA)

Ozempic®, Rybelsus®, Mounjaro®, Victoza®, Byetta, Bydureon®, Trulicity®

- If you take one of these seven drugs for **weight loss only**, it will no longer be covered.
- If you take Ozempic, Rybelsus, Mounjaro, Victoza, Byetta, Bydureon, or Trulicity for type 2 diabetes, it will continue to be covered if your pharmacy provider or prescriber submits a request and it is approved. If you take these drugs for other uses, check with your doctor.

Members Younger than 21 Years of Age

If a member who is younger than 21 years of age needs a GLP-1 drug for weight loss, it will continue to be covered if the member's pharmacy provider or prescriber submits a PA request and it is approved, due to federal Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) benefit requirements.



Medi-Cal Rx

Right to State Hearing

Medi-Cal members who receive a Notice of Action (NOA) denying coverage for GLP-1 drugs have the right to a State Hearing. Generally, Medi-Cal members have 90 days from the date of the NOA to submit a written request to the California Department of Social Services (CDSS) for a State Hearing, as communicated in the State Hearing rights provided with the NOA. Medi-Cal members who are taking GLP-1 drugs on or before January 1, 2026, who request a State Hearing within 10 days of receiving an NOA denying continued coverage may continue to receive GLP-1 drugs pending a State Hearing decision until the earlier of:

- The end of the period covered by their current PA; or
- The date a State Hearing decision is rendered; or
- The date on which the State Hearing is otherwise withdrawn or closed.

A State Hearing may be requested by contacting CDSS, State Hearings Division:

State Hearings

P.O. Box 944243, MS 21-37

Sacramento, CA 94244-2430

Toll Free: 1-800-743-8525 or 1-855-795-0634

Fax: 1-833-281-0905

Website: <https://www.cdss.ca.gov/hearing-requests>